Natalie Wildenradt | IR |
Geraldine Henwood | CEO, President & Director |
Ryan Lake | CFO |
David Amsellem | Piper Jaffray Companies |
Kenneth Trbovich | Janney Montgomery Scott |
Scott Henry | Roth Capital Partners |
Leland Gershell | Oppenheimer & Co. |
Patrick Trucchio | Berenberg Capital |
Good morning, and welcome to Recro Pharma Second Quarter 2018 Financial Results Conference Call. [Operator Instructions].
As a reminder, this conference is being recorded at the company's request. I would now like to turn the call over to Natalie Wildenradt, Investor Relations.
You may begin.